Vanguard Group Inc. Raises Position in ANI Pharmaceuticals, Inc. $ANIP

Vanguard Group Inc. boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,305,068 shares of the specialty pharmaceutical company’s stock after buying an additional 27,598 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of ANI Pharmaceuticals worth $103,022,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Hantz Financial Services Inc. lifted its stake in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares in the last quarter. State of Wyoming purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. CWM LLC lifted its stake in ANI Pharmaceuticals by 159.1% in the 3rd quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 490 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in ANI Pharmaceuticals by 30.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 253 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 2,060 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total transaction of $157,590.00. Following the completion of the sale, the senior vice president owned 84,782 shares in the company, valued at $6,485,823. This trade represents a 2.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the sale, the senior vice president owned 38,730 shares of the company’s stock, valued at $2,901,264.30. This represents a 10.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 27,860 shares of company stock worth $2,111,581. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Trading Up 1.0%

ANIP opened at $79.50 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The company’s 50 day simple moving average is $77.08 and its two-hundred day simple moving average is $80.70. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of 20.13 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period last year, the company posted $1.70 EPS. The business’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts expect that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ANIP shares. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.